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The Journal of Immunology
IL-33 Augments Virus-Specific Memory T Cell
Inflation and Potentiates the Efficacy of an Attenuated
Cytomegalovirus-Based Vaccine
James E. McLaren,* Mathew Clement,* Morgan Marsden,* Kelly L. Miners,*
Sian Llewellyn-Lacey,* Emma J. Grant,*,† Anzelika Rubina,* Silvia Gimeno Brias,*
Emma Gostick,* Maria A. Stacey,*,1 Selinda J. Orr,* Richard J. Stanton,*
Kristin Ladell,* David A. Price,*,2 and Ian R. Humphreys*,‡,2
Candidate vaccines designed to generate T cell–based immunity are typically vectored by nonpersistent viruses, which largely
fail to elicit durable effector memory T cell responses. This limitation can be overcome using recombinant strains of CMV. Proof-
of-principle studies have demonstrated the potential benefits of this approach, most notably in the SIV model, but safety concerns
require the development of nonreplicating alternatives with comparable immunogenicity. In this study, we show that IL-33
promotes the accumulation and recall kinetics of circulating and tissue-resident memory T cells in mice infected with murine
CMV. Using a replication-deficient murine CMV vector, we further show that exogenous IL-33 boosts vaccine-induced memory
T cell responses, which protect against subsequent heterologous viral challenge. These data suggest that IL-33 could serve as a
useful adjuvant to improve the efficacy of vaccines based on attenuated derivatives of CMV. The Journal of Immunology, 2019,
202: 000–000.
R
ecombinant viruses have been widely explored as vac-
cine vectors purposed to elicit T cell immunity (1–3).
In immunocompetent hosts, wild-type (WT) human CMV
(HCMV) typically establishes an asymptomatic, lifelong infection.
Unlike many other viruses, however, HCMV induces unusually
large T cell responses that expand over time, a process termed
“memory inflation” (4, 5). The majority of circulating HCMV-
specific CD4+ and CD8+ T cells display highly differentiated
phenotypes associated with the acquisition and rapid deployment
of antiviral effector functions (6, 7). Moreover, in vivo studies
have shown that murine CMV (MCMV) drives the formation of
tissue-resident memory T (TRM) cells (8–10). Coupled with the
ability of different strains to “superinfect” seropositive individuals
(11), these data prompted speculation that HCMV may serve as a
unique vector, enabling the generation of local and systemic T cell
immunity against heterologous Ags (12). This approach was
subsequently validated with astonishing results in the SIV model,
where vaccine-elicited effector memory T (TEM) cells protected
rhesus macaques from viral challenge and cleared established
infections (13–15). Similarly, replication-competent strains of
MCMV have been used as vectors to protect mice from Ebola
virus (16), HSV type 1 (17), and various cancers (18–20). However,
this strategy is limited in humans, where replication-competent
vaccines pose serious risks to immunocompromised recipients
and hold the potential to recombine unpredictably with naturally
occurring strains of HCMV. Accordingly, much effort has focused
on the development of replication-deficient alternatives (21–24).
Of particular note, glycoprotein L–deficient (DgL) MCMV vectors
have been shown to elicit sustained CD8+ TEM cell responses
(22–24), with demonstrable effects in murine cancer models (25).
These vectors nonetheless deliver a modest antigenic stimulus
compared with replication-competent strains of MCMV (22–24).
IL-33, a member of the IL-1 cytokine family, is released as a
danger signal or “alarmin” in response to infection or cellular
stress (26, 27) and exhibits a wide range of functions that aid
immune clearance of microbes and parasites (28). Although IL-33
can act in the nucleus of healthy nonhematopoietic cells, it signals
as an alarmin via ST2 and the IL-1R accessory protein, which
combine to form an active heterodimeric receptor on the surface
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of macrophages, NK cells, and T cells (28). Divergent immuno-
logical effects have been ascribed to IL-33. In some settings, it
induces regulatory T cell expansions (28–30), whereas in other
settings, it promotes antiviral T cell immunity (31–33). IL-33 can
also enhance the production of virus-specific Abs at mucosal
surfaces and boost the immunogenicity of DNA and protein-based
vaccines (31, 34–36). It is further notable that alum, a long-
established vaccine adjuvant, induces the release of IL-33 (37).
In this study, we show that IL-33 augments memory T cell
inflation and recall, as well as the formation of classically de-
fined (CD69+) TRM cells, in mice infected with MCMV. We also
demonstrate that IL-33 enhances replication-deficient (DgL)
MCMV vaccine-induced memory T cell responses, leading to
greater protection against subsequent heterologous viral chal-
lenge. Collectively, these data suggest that the translational ben-
efits of attenuated CMV-based vaccines can be potentiated by
alarmins, such as IL-33.
Materials and Methods
Mice, infections, and treatments
Il332/2 mice were bred in-house (38). C57BL/6 mice were purchased from
Charles River Laboratories or Envigo. Sex-matched mice aged 7–9 wk
were used in all experiments. Smith-strain MCMV was propagated in vivo
and prepared via sorbitol gradient purification (39). Mice were infected i.p.
with 3 3 104 PFU of MCMV. DgL-SL8-MCMV was prepared as de-
scribed previously (24). Mice were infected i.p. with 4 3 105 PFU of
DgL-SL8-MCMV. In some experiments, 2 mg of rIL-33 (BioLegend) was
administered i.p. at the time of infection. Replication-deficient recombi-
nant adenovirus type 5 (pAdZ5-CV5) expressing immediate-early protein
3 (rAd-IE3) was engineered and purified as described previously (40). Mice
were challenged i.p. with 5 3 108 PFU of rAd-IE3 or 2 3 106 PFU of
recombinant vaccinia virus expressing OVA (rVV-OVA) (41). All mouse
experiments were performed at Cardiff University under U.K. Home Office
Project License 30/2969 (London, U.K.).
Tetramers
Fluorochrome-tagged H-2Db/M45 (HGIRNASFI), H-2Kb/m139 (TVYGFCLL),
H-2Kb/M38 (SSPPMFRV), H-2Kb/IE3 (RALEYKNL), and H-2Kb/SL8
(SIINFEKL) tetramers were produced in-house as described previously (42).
Flow cytometry
Leukocytes were isolated from spleens, lungs, salivary glands, and inguinal
lymph nodes (LNs) as described previously (43). Peripheral blood was
collected from the lateral tail vein directly into heparin-coated tubes via an
integrated capillary (Sarstedt).
For phenotypic analyses of CD4+ and CD8+ T cells, leukocytes were
stained with LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific), in-
cubated with anti-CD16/CD32 Fc-block (BioLegend), and stained with
various combinations of the following mAbs: anti-CD62L–PE-Texas Red
(clone MEL-14; BD Biosciences); anti-CD69–PE-Cy7 (clone H1.2F3;
eBioscience); anti-KLRG-1–FITC (clone 2F1; Southern Biotech); and anti-
CD3ε–PE-Cy5 (clone 145-2C11), anti-CD4–allophycocyanin-Fire 750 (clone
RM4-5), anti-CD8a–BV711 (clone 53-6.7), anti-CD11a–allophycocyanin
(clone M17/4), anti-CD27–allophycocyanin (clone LG.3A10), anti-
CD44–PE-Cy7 (clone IM7), anti-CD62L–PE-Dazzle 594 (clone MEL-14),
anti-CD69–allophycocyanin (clone H1.2F3), anti-CD103–PE (clone 2E7),
anti-CD103–PE-Dazzle 594 (clone 2E7), and anti-PD-1–BV605 (clone
29F.1A12) (all from BioLegend). Ag-specific CD8+ T cells were prelabeled
with tetramer as indicated for 20 min at 37˚C (44).
The following mAbs were used to characterize dendritic cells (DCs),
myeloid cells, and NK cells: anti-I-A/I-E–Pacific Blue (clone M5/
114.15.2), anti-CD11b–FITC (clone M1/70), anti-CD11c–PE (clone
N418), anti-CD40–FITC (clone 3/23), anti-CD45R/B220–BV785 (clone
RA3-6B2), anti-CD80–allophycocyanin (clone 16-0A1), anti-CD86–
PE-Cy7 (clone GL-1), anti-F480–BV711 (clone BM8), anti-Ly6C–PE-Cy7
(clone HK1.4), anti-Ly6G–PE-Dazzle 594 (clone 1A8), anti-Ly49H–PE-
Cy7 (clone 3D10), anti-NK1.1–BV421 (clone PK136), and anti-SiglecH–
allophycocyanin (clone 551) (all from BioLegend).
For functional analyses of CD8+ T cells, leukocytes were stimulated for
6 h with the indicated peptide (M45, m139, M38, IE3, or SL8) at a fi-
nal concentration of 2 mg/ml in the presence of monensin (1:1500 stock
dilution; BD Biosciences), brefeldin A (2 mg/ml; BD Biosciences), and
anti-CD107a–FITC (clone 1D4B; BioLegend). Cells were then stained
with LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific), incubated
with anti-CD16/CD32 Fc-block (BioLegend), and stained with anti-CD4–
allophycocyanin-Fire 750 (clone RM4-5) and anti-CD8a–BV711 (clone
53-6.7) (both from BioLegend). After fixation/permeabilization using a
standard paraformaldehyde/saponin protocol, cells were further stained
intracellularly with anti-IFN-g–Pacific Blue (clone XMG1.2) and anti-
TNF-a–PE-Cy7 (clone MP6-XT22) (both from BioLegend).
Intravascular staining was performed using anti-CD8a–PE-Cy5 (clone
53-6.7; BioLegend) at a dose of 3 mg/mouse as described previously (8, 9, 45).
All data were acquired using a modified FACSAria II flow cytometer (BD
Biosciences) and analyzed with FlowJo software version 9.9.3 (Tree Star).
Real-time quantitative PCR
Total RNAwas extracted from cell populations and whole tissues using an
SV Total RNA Isolation Kit (Promega). cDNA was synthesized using
Superscript II (Thermo Fisher Scientific). Expression of Il33 was quanti-
fied using a MiniOpticon Real-Time PCR System (Bio-Rad Laboratories)
with Platinum SYBR Green Master Mix (Bio-Rad Laboratories). Specific
primers were described previously (43, 46). Expression of sphingosine-
1-phosphate receptor 1 (S1pr1) was quantified using a QuantStudio 3 Real-
Time PCR System (Applied Biosystems) with a TaqMan Gene Expression
Assay (Mm02619656_s1) and TaqMan Fast Advanced Master Mix (Ap-
plied Biosystems). All data were normalized to b-actin (ACTB).
Quantification of viral DNA
Saliva was obtained from anesthetized mice via oral lavage of the sublingual
cavity using 20 ml of PBS (47). Viral DNAwas quantified in 1 ml of sample
using an Ie1-specific quantitative PCR. DNA copies per microliter were
determined against a standard curve established using an MCMV pARK25
bacterial artificial chromosome (a kind gift from A. Redwood, Murdoch
University, Perth, Australia).
Statistical analysis
Data were evaluated for statistical significance using the Mann–Whitney
U test (two groups) or a one-way ANOVA followed by the Tukey post hoc
test (.2 groups) in Prism Mac 5.0f (GraphPad). Virus load data were
logarithmically transformed prior to analysis. Outliers were included in all
datasets. All p values are reported as follows: *p # 0.05, **p # 0.01, and
***p # 0.001.
Results
IL-33 is induced in lymphoid organs during acute MCMV
infection but is not required for early innate responses or the
induction of virus-specific CD8+ T cells
MCMV initially targets stromal cells in the marginal zone of
the spleen (48), which express high levels of IL-33 (26). Other
viruses, such as lymphocytic choriomeningitis virus (LCMV),
target fibroblastic reticular cells (49) and enhance Il33 gene ex-
pression (31). We found that Il33 was upregulated in the spleen
and inguinal LNs, but not the lung, during acute MCMV infection
(Fig. 1A). Alongside previously reported data (50, 51), these re-
sults suggest that MCMV induces Il33 expression in fibroblastic
reticular cells, which are not present in mucosal tissues (52). In
contrast, the replication-deficient strain DgL-MCMV did not sig-
nificantly upregulate Il33 (Fig. 1A).
IL-33 can influence the development and function of NK cells
(50) and APCs (28, 53, 54), which act synergistically to provide
acute-phase antiviral immunity (55, 56). To investigate these ef-
fects in the context of MCMV, we infected WT and Il332/2 mice
(38) and measured the accumulation of Ly49H+ NK cells
(Fig. 1B), which limit viral replication in this model (57), B cells
(Supplemental Fig. 1A), and various subsets of DCs, including
conventional DCs (cDCs) and plasmacytoid DCs (Fig. 1C). No
clear differences in absolute cell numbers were observed between
WT and Il332/2 mice. Moreover, Ly49H+ NK cells were activated
to a similar extent in WT and Il332/2 mice (Supplemental Fig. 1B),
and pairwise comparisons of CD11b+ and CD8a+ cDCs across
strains revealed comparable expression levels of MHC class II and
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the costimulatory molecules CD40, CD80, and CD86 (Supplemental
Fig. 1C). These findings suggest that MCMV triggers innate re-
sponses independently of IL-33.
IL-33 promotes antiviral CD8+ T cell immunity during acute
LCMV infection (31). To extend this observation, we characterized
MCMV-specific CD8+ T cell responses in WTand Il332/2mice using
MHC class I–peptide tetramers corresponding to the noninflationary
H-2Db–restricted M45 epitope and the inflationary H-2Kb–restricted
m139, M38, and IE3 epitopes (58). On day 7 postinfection, similar
numbers of MCMV-specific CD8+ T cells were detected per site in the
spleens, lungs, salivary glands, and inguinal LNs of WT and Il332/2
mice (Fig. 1D). The frequencies of M45-specific and M38-specific
CD8+ T cells in peripheral blood were also unaffected by a lack of
IL-33 (Fig. 1E). In both strains of mice, all MCMV-specific CD8+
T cells displayed an Ag-experienced (CD44hiCD62Llo) TEM phenotype,
irrespective of specificity and tissue origin (Fig. 1F). Moreover, the total
FIGURE 1. IL-33 is induced in lymphoid organs during acute MCMV infection but is not required for early innate responses or the induction of
virus-specific CD8+ T cells. (A) C57BL/6 mice were infected with MCMV (WT) or DgL-SL8-MCMV. Spleens, lungs, and inguinal LNs were isolated
on day 2 or day 4 postinfection (pi). Naive mice were used as the day 0 control. Expression of Il33 was measured using a real-time quantitative PCR.
Absolute values were normalized to ACTB. Data are shown as mean 6 SEM (n = 4 mice per group). *p # 0.05, **p # 0.01. (B–F) C57BL/6 (WT) and
Il332/2 mice were infected with MCMV. (B) Total numbers of Ly49H+ NK cells (CD3–NK.1.1+) were quantified among leukocytes isolated from
spleens on day 4 pi. Data are shown as mean 6 SEM (n = 5 mice per group). (C) Total numbers of DCs (CD3–CD11c+MHCII+) were quantified among
leukocytes isolated from spleens on day 4 pi as follows: plasmacytoid DCs (pDCs) (B220+CD11b–Ly6C+SigLec-H+), CD11b+ cDCs (B220–CD8a–CD11b+),
and CD8a+ cDCs (B220–CD8a+CD11b–). Data are shown as mean 6 SEM (n = 5 mice per group). (D) Total numbers of tetramer-binding CD8+
T cells specific for M45, m139, M38, or IE3 were quantified among leukocytes isolated from spleens, lungs, salivary glands, and inguinal LNs on day
7 pi. Data are shown as mean 6 SEM (n = 5 mice per group). (E) Frequencies of tetramer-binding CD8+ T cells specific for M45 or M38 were
quantified in peripheral blood on day 7 pi. Horizontal bars depict mean percentage of viable CD3+CD8+ T cells (n = 7 mice per group). (F) Expression
levels of CD44 and CD62L were quantified on tetramer-binding CD8+ T cells specific for M45 or m139 among leukocytes isolated from spleens on
day 7 pi. Representative flow cytometry plots are shown. Ag-specific events are depicted as colored dots superimposed on black density plots
encompassing all CD8+ T cells. (G) Viral genomes were quantified in saliva via quantitative PCR on day 14 pi. Horizontal bars depict median log10
DNA copies per microliter (n = 7 mice per group). All results are shown (A–E and G).
The Journal of Immunology 3
 by guest on January 18, 2019
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
numbers of CD4+ and CD8+ T cells in lymphoid organs and mucosal
tissues were comparable between WT and Il332/2mice (Supplemental
Fig. 1D). These data suggest that IL-33 is not required for the induction
of CD8+ T cell immunity during acute MCMV infection.
In line with these findings, equivalent levels of viral DNA were
detected in WT and Il332/2 mice on day 14 postinfection
(Fig. 1G). Similar results were reported previously in a study of
St22/2 BALB/c mice (51).
Endogenous IL-33 promotes MCMV-specific CD8+ memory
T cell inflation and the accumulation of CD69+ TRM cells
Chronic MCMV infection drives systemic CD8+ memory T cell
inflation and the accumulation of virus-specific CD4+ and CD8+
TRM cells in mucosal tissues (8–10). CD4
+ TRM cells typically
express CD11a and CD69, whereas CD8+ TRM cells typically
express CD69 either alone or in conjunction with CD103 (8, 59).
It has also been shown that IL-33 can upregulate the expression of
CD69 on T cells, at least in vitro (9, 60). We therefore assessed the
impact of IL-33 on the development of MCMV-specific TEM and
TRM cells in vivo.
On day 60 postinfection, lower frequencies of IE3-specific CD8+
T cells were present in the spleens of Il332/2 mice relative to WT
mice, and a corresponding trend was observed in the lungs and
salivary glands (Fig. 2A). Similarly, lower numbers of IE3-specific
CD8+ T cells were present in the lungs of Il332/2 mice relative to
WT mice, and a corresponding trend was observed in the spleens
FIGURE 2. Il332/2 mice exhibit impaired virus-specific CD8+ memory T cell inflation during chronic MCMV infection. C57BL/6 (WT) and Il332/2 mice
were infected with MCMV. (A) Frequencies of tetramer-binding CD8+ T cells specific for M45, m139, M38, or IE3 were quantified among leukocytes isolated
from spleens, lungs, and salivary glands on day 60 postinfection (pi). Horizontal bars depict mean percentage of viable CD3+CD8+ T cells (n = 9 mice per
group). (B) Total numbers of tetramer-binding CD8+ T cells specific for M45, m139, M38, or IE3 were quantified among leukocytes isolated from spleens,
lungs, and salivary glands on day 60 pi. Data are shown as mean6 SEM (n = 12–16 mice per group). (C) Total numbers of naive (TN) and memory T (TEM and
TCM) cells within the CD4
+ and CD8+ compartments were quantified among leukocytes isolated from spleens, lungs, and salivary glands on day 60 pi. Data are
shown as mean 6 SEM (n = 9–12 mice per group). Results are concatenated from three independent experiments (A–C). *p # 0.05, ***p # 0.001.
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and salivary glands (Fig. 2B). The total numbers of CD4+ and
CD8+ T cells, especially within the TEM compartment, were
also lower in the lungs of Il332/2 mice relative to WT mice
(Fig. 2C). No significant differences were observed among
tissues in parallel analyses of CD8+ T cells specific for M45,
m139, or M38.
In the spleens and lungs of WT and Il332 /2 mice chronically
infected with MCMV, the vast majority of CD8+ T cells were
CD69–CD103– or CD69–CD103+ (Supplemental Fig. 2A).
Virus-specific inflationary CD8+ T cells in these organs were
also predominantly CD69–CD103–, as reported previously (8,
9), with no discernible phenotypic differences between WT
and Il332 /2 mice (Supplemental Fig. 2B). However, in the
salivary glands, where CD69+ TRM cells accumulate during
chronic MCMV infection (8, 9), the frequencies (Fig. 3A, 3B)
and total numbers (Fig. 3C) of CD8+ TRM (CD69
+CD103– or
CD69+CD103+) cells were greatly reduced in Il332 /2 mice.
The frequencies of inflationary MCMV-specific CD8+ TRM
cells with a CD69+CD103+ phenotype, especially those spe-
cific for IE3, were also reduced in Il332 /2 mice (Fig. 3D, 3E),
although no significant differences were observed with re-
spect to overall numbers (Supplemental Fig. 2C). Similarly,
the frequencies of CD4+ TRM (CD11a
+CD69+) cells were
lower in the salivary glands of Il332/2 mice relative to WT mice
(Fig. 3F, 3G).
Collectively, these data identify IL-33 as an important mediator
of virus-specific CD8+ memory T cell inflation and CD69+ TRM
cell formation during chronic MCMV infection.
IL-33–driven upregulation of CD69 is not required for the
retention of CD8+ TRM cells during chronic MCMV infection
CD69 is commonly used as a marker to distinguish bona fide TRM
cells from recirculating TEM cells (61), but tissue residency per se is
not defined by the expression of CD69 (62). We therefore used
intravascular staining to determine if Il332/2 mice truly lack the
ability to generate CD8+ TRM cells after infection with MCMV. In
WT mice, tissue-localized CD8+ T cells predominated in the sali-
vary glands, as reported previously (8, 9), whereas intravascular
CD8+ T cells predominated in the lungs (Supplemental Fig. 2D,
2E). A similar pattern was observed in Il332/2 mice chronically
infected with MCMV (Supplemental Fig. 2D, 2E). Moreover,
comparable frequencies of CD69–CD103– and CD69–CD103+
CD8+ T cells were retained in the salivary glands of WT and Il332/2
mice (Supplemental Fig. 2F).
Tissue egress is mediated by S1PR1, which is downregulated by
CD69 (63). To examine the role of IL-33 in this process, we
measured S1pr1 expression in flow-purified CD69–CD103+ and
CD69+CD103+ CD8+ T cells isolated from the salivary glands of
WT and Il33–/– mice chronically infected with MCMV. In both
strains of mice, CD69–CD103+ CD8+ T cells expressed higher
FIGURE 3. Endogenous IL-33 promotes the accumulation of CD69+ TRM cells during chronic MCMV infection. C57BL/6 (WT) and Il33
2/2 mice were
infected with MCMV. (A) Expression levels of CD69 and CD103 were quantified on CD8+ T cells among leukocytes isolated from salivary glands on day 60
postinfection (pi). Data are shown as mean 6 SEM (n = 9 mice per group). (B) Expression levels of CD69 and CD103 were quantified on CD8+ T cells among
leukocytes isolated from spleens and salivary glands on day 60 pi. Representative flow cytometry plots are shown. (C) Total numbers of CD8+ TRM
(CD69+CD103– or CD69+CD103+) cells were quantified among leukocytes isolated from salivary glands on day 60 pi. Data are shown as mean 6 SEM (n = 9
mice per group). (D) Expression levels of CD69 and CD103 were quantified on tetramer-binding CD8+ T cells specific for m139, M38, or IE3 among leukocytes
isolated from salivary glands on day 60 pi. Representative flow cytometry plots are shown. Ag-specific events are depicted as colored dots superimposed on black
density plots encompassing all CD8+ T cells. (E) Expression levels of CD69 and CD103 were quantified on tetramer-binding CD8+ T cells specific for m139,
M38, or IE3 among leukocytes isolated from salivary glands on day 60 pi. Data are shown as mean 6 SEM (n = 9 mice per group). (F) Expression levels of
CD11a and CD69 were quantified on CD4+ T cells among leukocytes isolated from salivary glands on day 60 pi. Representative flow cytometry plots are shown.
(G) Frequencies of CD4+ T cells expressing CD11a and CD69 were quantified among leukocytes isolated from salivary glands on day 60 pi. Data are shown as
mean 6 SEM (n = 9–12 mice per group). Results are concatenated from three independent experiments (A, C, E, and G). *p # 0.05, **p # 0.01.
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levels of S1pr1 than CD69+CD103+ CD8+ T cells, although
these differences lacked significance in pairwise comparisons
(Supplemental Fig. 2G). Moreover, CD69–CD103+ CD8+ T cells
expressed higher levels of S1pr1 in Il33–/– mice relative to
WT mice, albeit just below the threshold for significance
(Supplemental Fig. 2G).
Collectively, these data suggest that IL-33 is not mandatory for
the retention of CD8+ TRM cells during chronic MCMV infection,
potentially because a subsidiary mechanism fulfills this role in-
dependently of CD69 (64).
Exogenous IL-33 enhances MCMV-specific CD8+ memory
T cell inflation and the accumulation of CD69+ TRM cells
Early immunological signals can modulate the development of
MCMV-specific memory T cells (65–67). On this basis, we ad-
ministered a single dose (2 mg) of rIL-33 at the time of MCMV
infection and enumerated virus-specific CD8+ T cells in WT mice.
In line with our studies of Il332/2 mice (Fig. 1D–F), rIL-33 did
not influence virus-specific CD8+ T cell responses in the spleen
during acute MCMV infection (Supplemental Fig. 3A, 3B). On
day 7 postinfection, however, greater numbers of IE3-specific
CD8+ T cells were present in the inguinal LNs of mice treated
with rIL-33 (Supplemental Fig. 3C). A similar pattern was ob-
served across naive and memory subsets of CD8+ T cells
(Supplemental Fig. 3D). Moreover, rIL-33 greatly enhanced the
numbers of inflationary MCMV-specific (Fig. 4A) and total (Fig.
4B) CD8+ T cells in the spleen during chronic MCMV infection
(day 60 postinfection), all of which retained a predominant
CD44hiCD62Llo phenotype (Fig. 4C). A corresponding increase in
the numbers of functional (CD107a+ and/or IFN-g+) inflationary
MCMV-specific CD8+ T cells was also detected in mice treated
with rIL-33 (Fig. 4D). In addition, rIL-33 enhanced the numbers
of inflationary MCMV-specific CD8+ T cells in mucosal tissues
(Fig. 4A), alongside a generic increase in the accumulation
of total CD8+ T cells, especially within the TEM compartment
(Fig. 4B).
Endogenous IL-33 promotes the accumulation of CD69+ TRM
cells in the salivary glands during chronic MCMV infection
(Fig. 3). In line with this finding, rIL-33 enhanced the frequen-
cies of IE3-specific CD8+ TRM (CD69
+CD103+) cells (Fig. 4E),
although corresponding increases in the numbers of inflationary
MCMV-specific CD8+ TRM and TEM cells failed to achieve
significance (Fig. 4F, 4G).
Collectively, these data suggest that rIL-33 can influence Ag-
driven priming events during acute MCMV infection to enhance
virus-specific CD8+ memory T cell inflation and the accumulation
of CD69+ TRM cells during chronic MCMV infection.
Exogenous IL-33 augments the immunogenicity and efficacy of
a model DgL-MCMV–based vaccine
Replication-competent CMV vectors are highly potent immuno-
gens, delivering remarkable efficacy as preventive and therapeutic
vaccines in multiple settings (10–20). However, safety con-
cerns mandate the development of nonreplicating alternatives
for widespread use in human populations. Although the
replication-deficient strain DgL-MCMV drives virus-specific
memory T cell inflation in mice, it remains substantially less
immunogenic than replication-competent strains of MCMV
(22–24). In light of our results with rIL-33, we hypothesized
that similar effects could be harnessed to augment the immu-
nogenicity and efficacy of a model DgL-MCMV–based vaccine,
especially as viral replication is required to induce endogenous
IL-33 expression in the spleens and inguinal LNs of acutely infected
mice (Fig. 1A). To test this idea, we immunized mice with a
recombinant DgL-MCMVexpressing the H2-Kb–restricted SIINFEKL
(SL8) epitope (DgL-SL8-MCMV) derived from OVA (24). A
mock adjuvant (PBS) or a single dose of rIL-33 (2 mg) was ad-
ministered in parallel at the time of infection (Fig. 5A). After 92 d,
mice were challenged with rVV-OVA (41, 68).
Mice immunized with DgL-SL8-MCMV plus rIL-33 exhibited
no obvious weight loss during acute infection, suggesting a good
adjuvant safety profile with no obvious toxicity, in contrast to mice
immunized with WT MCMV plus rIL-33 (Fig. 5B). The vector
itself elicited higher frequencies of circulating CD8+ T cells
specific for M38 and IE3 in mice immunized with DgL-SL8-
MCMV plus rIL-33 relative to mice immunized with DgL-SL8-
MCMV plus PBS, although these differences were modest and
largely fell below the threshold for significance (Fig. 5C). The
frequencies of circulating SL8-specific CD8+ T cells, most of
which displayed a TEM phenotype (Supplemental Fig. 4A), also
increased over time to a greater extent in the DgL-SL8-MCMV
plus rIL-33 group compared with the DgL-SL8-MCMV plus PBS
group (Fig. 5C). Encouragingly, these insert-specific differences
were significant at early (day 7) and late (day 60) time points
after immunization with DgL-SL8-MCMV. In addition, the
circulating frequencies of total CD8+ TEM cells were initially
higher in mice immunized with DgL-SL8-MCMV plus rIL-33
relative to mice immunized with DgL-SL8-MCMV plus PBS
(Supplemental Fig. 4B).
In response to rVV-OVA challenge, naive mice generated
nominal frequencies (Fig. 5D, 5E) and total numbers (Fig. 5F) of
SL8-specific CD8+ T cells in the spleen, lungs, and ovaries, which
are the major sites of viral replication in this model (41, 69).
Substantially greater recall responses were detected in mice im-
munized with DgL-SL8-MCMV (Fig. 5D–F). Moreover, rIL-33
amplified these recall responses, such that higher frequencies
(Fig. 5D, 5E) and numbers (Fig. 5F) of SL8-specific CD8+ T cells
were present in the spleens, lungs, and ovaries of mice immunized
with DgL-SL8-MCMV plus rIL-33 relative to mice immunized
with DgL-SL8-MCMV plus PBS. In addition, rIL-33 substan-
tially enhanced the total numbers of CD4+ and CD8+ TEM cells
in the spleens, lungs, and ovaries of mice immunized with
DgL-SL8-MCMV (Supplemental Fig. 4C–F). To contextualize
these results, a single dose of rIL-33 administered at the time of
immunization with DgL-SL8-MCMV magnified the total SL8-
specific CD8+ T cell response to rVV-OVA challenge by 4.1-fold
in the spleen, 4.4-fold in the lungs, and 5.6-fold in the ovaries (Fig.
5F). Of note, rIL-33 also marginally enhanced the MCMV-specific
CD8+ T cell response after challenge with rVV-OVA (Fig. 5G,
Supplemental Fig. 4G).
Immunization with DgL-SL8-MCMV enhanced the functional
profile of SL8-specific CD8+ T cells responding to rVV-OVA
challenge (Fig. 6A). As a consequence, greater numbers of mono-
functional (CD107a+, IFN-g+, or TNF-a+) and polyfunctional
(CD107a+IFN-g+ or CD107a+IFN-g+TNF-a+) SL8-specific
CD8+ T cells were present in the spleens of immunized mice
relative to nonimmunized mice (Fig. 6B). Moreover, greater
numbers of monofunctional and polyfunctional SL8-specific
CD8+ T cells were present in the spleens of mice immunized
with DgL-SL8-MCMV plus rIL-33 relative to mice immunized
with DgL-SL8-MCMV plus PBS (Fig. 6A, 6B). Vaccine-induced
SL8-specific CD8+ T cells responding to rVV-OVA challenge
displayed lower expression levels of CD27 and PD-1 and
higher expression levels of KLRG-1 compared with de novo
SL8-specific CD8+ T cells responding to rVV-OVA challenge
(Fig. 6C). These phenotypic trends were further emphasized
in mice immunized with DgL-SL8-MCMV plus rIL-33 (Fig. 6C).
Greater numbers of SL8-specific CD8+ T cells with a
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CD27loKLRG-1hi memory phenotype were therefore present in
the spleens of mice immunized with DgL-SL8-MCMV plus
rIL-33 relative to mice immunized with DgL-SL8-MCMV plus
PBS (Fig. 6D, 6E). Such effector-like cells have previously been
associated with protection against pathogenic challenge (70).
Systemic challenge with recombinant VV leads to viral repli-
cation in the ovaries, and immune protection is conferred by
Ag-specific CD8+ T cells (69). Accordingly, we used a plaque
assay to quantify replicating rVV-OVA in the ovaries of naive and
immunized mice. Vaccination substantially reduced virus load
after challenge with rVV-OVA (Fig. 6F). Moreover, rIL-33 further
enhanced immune control, such that lower virus loads were ob-
served in mice immunized with DgL-SL8-MCMV plus IL-33
relative to mice immunized with DgL-SL8-MCMV plus PBS
(Fig. 6F).
Collectively, these data show that rIL-33 can augment the
immunogenicity and efficacy of a DgL-MCMV–based vaccine
designed to elicit CD8+ memory T cells with antiviral ef-
fector functions that protect against subsequent heterologous
challenge.
FIGURE 4. Exogenous IL-33 enhances virus-specific memory T cell inflation and the accumulation of CD69+ TRM cells during chronic MCMV infection.
C57BL/6 mice were infected with MCMValongside a single dose of rIL-33 (2 mg) or volume-equivalent PBS. (A) Total numbers of tetramer-binding CD8+ T cells
specific for M45, m139, M38, or IE3 were quantified among leukocytes isolated from spleens, lungs, and salivary glands on day 60 postinfection (pi). Data are
shown as mean 6 SEM (n = 5–9 mice per group). (B) Total numbers of naive (TN) and memory T (TEM and TCM) cells within the CD8
+ compartment were
quantified among leukocytes isolated from spleens, lungs, and salivary glands on day 60 pi. Data are shown as mean 6 SEM (n = 5–9 mice per group). (C)
Expression levels of CD44 and CD62L were quantified on tetramer-binding CD8+ T cells specific for M45, m139, M38, or IE3 among leukocytes isolated from
spleens on day 60 pi. Representative flow cytometry plots are shown. Ag-specific events are depicted as colored dots superimposed on black density plots
encompassing all CD8+ T cells. (D) Total numbers of functional (CD107a+ or IFN-g+) CD8+ T cells specific for M45, m139, M38, or IE3 were quantified among
leukocytes isolated from spleens on day 60 pi. Data are shown as mean6 SEM (n = 4 mice per group). (E) Expression levels of CD69 and CD103 were quantified
on tetramer-binding CD8+ T cells specific for M45, m139, M38, or IE3 among leukocytes isolated from salivary glands on day 60 pi. Data are shown as mean 6
SEM (n = 5 mice per group). (F) Total numbers of tetramer-binding CD8+ TRM (CD69
+CD103– or CD69+CD103+) cells specific for m139, M38, or IE3 were
quantified among leukocytes isolated from salivary glands on day 60 pi. Data are shown as mean 6 SEM (n = 5 mice per group). (G) Total numbers of tetramer-
binding CD8+ TEM (CD44
hiCD62Llo) cells specific for M38 or IE3 were quantified among leukocytes isolated from salivary glands on day 60 pi. Data are shown as
mean 6 SEM (n = 5 mice per group). Results are concatenated from two independent experiments (A, B, and D–G). *p # 0.05, **p # 0.01, ***p # 0.001.
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FIGURE 5. Exogenous IL-33 boosts the immunogenicity of DgL-SL8-MCMV. Female C57BL/6 mice were infected with DgL-SL8-MCMValongside a
single dose of rIL-33 (2 mg) or volume-equivalent PBS. (A) Schematic representation of the experimental protocol. Peripheral blood was drawn on day 7,
day 30, and day 60 postinfection (pi). Mice were challenged with rVV-OVA on day 92 pi. Spleens, lungs, and ovaries were harvested on day 97 pi. Naive
mice were challenged in parallel as controls. (B) Body weight was measured in each group of DgL-SL8-MCMV–infected mice and the corresponding
groups of WT MCMV-infected mice. Data are shown as mean6 SEM (n = 7 mice per group). (C) Frequencies of tetramer-binding CD8+ T cells specific for
M38, IE3, or SL8 were quantified in peripheral blood on day 7, day 30, and day 60 pi. Data are shown as mean 6 SEM (n = 3–8 mice per group).
(D) Frequencies of tetramer-binding CD8+ T cells specific for SL8 were quantified among leukocytes isolated from ovaries on day 5 postchallenge
(day 97 pi). Representative flow cytometry plots are shown. (E) Frequencies of tetramer-binding CD8+ T cells specific for SL8 were quantified among leukocytes
isolated from spleens, lungs, and ovaries on day 5 postchallenge (day 97 pi). Data are shown as mean 6 SEM (n = 3–8 mice (Figure legend continues)
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Endogenous IL-33 promotes anamnestic MCMV-specific CD8+
memory T cell responses
Memory recall is a key determinant of effective local and systemic
immunity (59). Accordingly, we tested the hypothesis that IL-33
can enhance virus-specific CD8+ memory T cell responsiveness to
secondary Ag encounter, based on our evaluation of mice im-
munized with DgL-SL8-MCMV. For this purpose, we infected
WT and Il332/2 mice with MCMVand measured recall responses
triggered by rAd-IE3 (Fig. 7A). To ensure comparability across
strains, challenge experiments were performed on day 30 postin-
fection, a time point at which equivalent frequencies of circulating
IE3-specific CD8+ T cells were present in WT and Il332/2 mice
(Fig. 7B). Low frequencies (Fig. 7C, 7D) and numbers (Fig. 7E) of
IE3-specific CD8+ T cells were detected in the spleens, lungs, and
peripheral blood of naive WT and Il332/2 mice after challenge
with rAd-IE3. In contrast, substantially higher frequencies
(Fig. 7B–D) and numbers (Fig. 7E) of IE3-specific CD8+ T cells
were present in the spleens, lungs, and peripheral blood of
MCMV-infected WT mice after challenge with rAd-IE3. No such
differences were observed with respect to the frequencies of
m139-specific CD8+ T cells (Fig. 7B). In addition, memory recall
was dramatically impaired in the absence of endogenous IL-33,
consistent with our initial predictions, such that lower frequencies
(Fig. 7B–D) and numbers (Fig. 7E) of IE3-specific CD8+ T cells were
present in the spleens, lungs, and peripheral blood of Il332/2 mice
relative to WT mice after challenge with rAd-IE3.
Collectively, these data show that IL-33 can promote anamnestic
CD8+ memory T cell responses during chronic MCMV infection,
illustrated in the context of heterologous challenge with a single
epitope derived from IE3.
Discussion
In this study, we investigated the immunomodulatory effects of
IL-33 in mice infected with MCMV. The key findings were: 1)
endogenous IL-33 promotes virus-specific CD8+ memory T cell
inflation and the accumulation of CD69+ TRM cells; 2) exogenous
IL-33 further enhances virus-specific CD8+ memory T cell infla-
tion and the accumulation of CD69+ TRM cells; 3) exogenous
IL-33 augments the immunogenicity and efficacy of a model
vaccine based on a replication-deficient strain of MCMV; and 4)
endogenous IL-33 promotes anamnestic virus-specific CD8+
memory T cell responses. These data identify IL-33 as an im-
portant mediator of antiviral T cell immunity and suggest that
alarmins may find utility as adjuvants in the context of emerging
vaccines based on attenuated derivatives of CMV.
IL-33 provides a danger signal that alerts the immune system to
viral attack (31, 32, 50, 51, 53, 71). In agreement with previous
studies (50, 51), we found that IL-33 was produced in the spleen
and inguinal LNs in response to systemic infection with MCMV.
Moreover, active viral replication was required to induce IL-33.
Despite this innate response, exogenous IL-33 administered at the
time of virus inoculation further enhanced memory T cell inflation
and the induction of CD69+ TRM cells during chronic infection,
raising the possibility of an unknown viral escape mechanism
designed to subvert T cell immunity (72). However, exogenous
IL-33 induced substantial weight loss in mice infected with
replication-competent MCMV. These observations suggest that
immune enhancement may be counteracted in excess by the
proinflammatory properties of IL-33.
In contrast to a recent study of St22/2 BALB/c mice (51),
we found that IL-33 was not required for the induction of
virus-specific CD8+ T cell responses during acute MCMV infection.
Our data nonetheless concur with the observation that immune
control of viral replication was not impacted by the lack of ST2
(51). We also found that Ly49H+ NK cells accumulated in the
spleen irrespective of IL-33, again in apparent disagreement
with earlier studies using different models (50). In contrast,
protective CD8+ T cells are critically dependent on IL-33 and
ST2 during acute infection with LCMVor VV (31). It is notable
in this context that CD4+ T cell help is not required for the in-
duction of virus-specific CD8+ T cell responses to LCMV or
MCMV (73–75). However, these viruses differ markedly with
respect to Ag presentation, which in turn may impact the sen-
sitivity of immune priming events to IL-33. In particular,
MCMV-specific CD8+ T cells are primed by DCs capable of
cross-presentation, such as lymphoid-resident CD8a+ cDCs (76,
77). Our data further show that CD8a+ cDCs are not depleted in
Il332/2 mice. In contrast, LCMV-specific CD8+ T cells can be
primed by APCs other than DCs (78), such as macrophages (79)
and nonhematopoietic cells (80).
A different picture emerged from the dataset acquired during
chronic MCMV infection. In this setting, lower frequencies and
numbers of virus-specific CD8+ T cells were detected in the lym-
phoid organs and mucosal tissues of Il332/2 mice relative to WT
mice. Moreover, a single dose of rIL-33 administered at the time of
infection further enhanced CD8+ memory T cell inflation. These
phenomena most evidently affected IE3-specific CD8+ memory
T cells, which are particularly dependent on CD4+ T cell help (73).
Although the causative mechanisms remain unknown, we noted that
MCMV-specific CD8+ T cells, especially those with a central
memory (TCM) phenotype, accumulated to a greater extent in the
peripheral LNs of mice treated with rIL-33. This observation is
pertinent in light of the prevailing view that memory inflation is
driven by replenishment from a pool of virus-specific TCM cells
exposed to continual stimulation from infected nonhematopoietic
cells in the peripheral lymphoid compartment (81, 82).
Virus-specific CD4+ and CD8+ TRM cells are recruited to
mucosal tissues during MCMV infection (8–10). Earlier work
further identified IL-33 as an important driver of the TRM phe-
notype (9, 60, 64), alongside TGF-b (8, 83–85). In line with
these observations, we found lower frequencies and total num-
bers of CD8+ TRM (CD69
+CD103– or CD69+CD103+) cells in
the salivary glands of Il332/2 mice relative to WT mice. The
frequencies of inflationary MCMV-specific CD8+ TRM cells with
a CD69+CD103+ phenotype, especially those specific for IE3,
were also reduced in the salivary glands of Il332/2 mice relative
to WT mice. However, these effects did not extend to tissue-
localized CD69–CD103– and CD69–CD103+ CD8+ T cells,
which were retained at comparable frequencies in both strains
of mice. Of note, TGF-b does not influence the expression of
CD69 on TRM cells (9, 60), but it can upregulate CD103 (8),
which is nonetheless dispensible for tissue-resident immu-
nity against MCMV (8, 9). In parallel evaluations, we
found that the accumulation of CD4+ TRM (CD11a
+CD69+)
per group). (F) Total numbers of tetramer-binding CD8+ T cells specific for SL8 were quantified among leukocytes isolated from spleens, lungs, and ovaries
on day 5 postchallenge (day 97 pi). Data are shown as mean6 SEM (n = 3–8 mice per group). (G) Total numbers of tetramer-binding CD8+ T cells specific
for M45, m139, M38, IE3, or SL8 were quantified among leukocytes isolated from spleens on day 5 postchallenge (day 97 pi). Data are shown as mean 6
SEM (n = 3–8 mice per group). Results are concatenated from two independent experiments (B, C, and E–G). *p # 0.05, **p # 0.01, ***p # 0.001.
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cells was similarly impaired in the salivary glands of Il332 /2
mice relative to WT mice. Overall, these data are consistent
with the notion that IL-33 positively regulates the genera-
tion of CD69+ TRM cells in response to systemic infection
with MCMV.
Attenuated derivatives of CMV have shown promise as novel
vaccine vectors in model systems (25). However, clinical development
will likely be hampered by key limitations, most notably a relative
lack of immunogenicity compared with replication-competent strains
of CMV. To overcome this potential bottleneck, we investigated the
immunomodulatory effects of rIL-33, which has been used previously
as a vaccine adjuvant (31, 34–36). In line with the observation that
viral replication is required to induce endogenous IL-33, we found
that the immunogenicity of DgL-SL8-MCMV was enhanced by a
single dose of rIL-33. After subsequent heterologous challenge,
greater numbers of SL8-specific CD8+ T cells were also present in
FIGURE 6. Exogenous IL-33 augments the protective efficacy of DgL-SL8-MCMV. Female C57BL/6 mice were infected with DgL-SL8-MCMValongside
a single dose of rIL-33 (2 mg) or volume-equivalent PBS and challenged with rVV-OVA on day 92 postinfection (pi) as depicted in Fig. 5A. (A) Functional
profiles of CD8+ T cells specific for SL8 were characterized among leukocytes isolated from spleens on day 5 postchallenge (day 97 pi). Combination gates
were exported into Simplified Presentation of Incredibly Complex Evaluations (SPICE) software (https://niaid.github.io/spice/). Pie chart segments represent the
fraction of cells expressing the number of functions indicated in the key. Arcs denote individual functions (CD107, IFN-g, and TNF-a). Concatenated data are
shown (n = 3–8 mice per group). (B) Total numbers of monofunctional (CD107a+, IFN-g+, or TNF-a+) and polyfunctional (CD107a+IFN-g+ or CD107a+IFN-
g+TNF-a+) CD8+ T cells specific for SL8 were quantified among leukocytes isolated from spleens on day 5 postchallenge (day 97 pi). Data are shown as mean
6 SEM (n = 3–8 mice per group). (C) Expression levels of KLRG-1, CD27, and PD-1 were quantified on tetramer-binding CD8+ T cells specific for SL8 among
leukocytes isolated from spleens on day 5 postchallenge (day 97 pi). Representative overlay histograms are shown. (D) Expression levels of KLRG-1 and CD27
were quantified on tetramer-binding CD8+ T cells specific for SL8 among leukocytes isolated from spleens and ovaries on day 5 postchallenge (day 97 pi).
Representative flow cytometry plots are shown. Ag-specific events are depicted as colored dots superimposed on black density plots encompassing all CD8+
T cells. (E) Total numbers of KLRG-1hiCD27lo tetramer-binding CD8+ T cells specific for SL8 were quantified among leukocytes isolated from spleens and
ovaries on day 5 postchallenge (day 97 pi). Data are shown as mean 6 SEM (n = 3–8 mice per group). (F) Replicating rVV-OVA titers were quantified in
ovaries isolated on day 5 postchallenge (day 97 pi). Horizontal bars depict median PFU per organ (n = 3–8 mice per group). Results are concatenated from two
independent experiments (A, B, E, and F). *p # 0.05, **p # 0.01, ***p # 0.001.
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the spleens, lungs, and ovaries of mice immunized with DgL-SL8-
MCMV plus rIL-33 relative to mice immunized with DgL-SL8-
MCMV plus PBS. These adjuvant effects were associated with
better control of rVV-OVA. In a further series of experiments con-
trolled for variable inflation, we found that endogenous IL-33 was
required for optimal virus-specific CD8+ memory T cell responses to
secondary Ag exposure, delivered in the form of rAd-IE3. Moreover,
rIL-33 enhanced CD4+ memory T cell formation in response to
DgL-SL8-MCMV. It is notable in this light that CD4+ T cell help can
promote the responsiveness of MCMV-specific CD8+ T cells (74).
Accordingly, rIL-33 may act both directly and indirectly to boost the
protective efficacy of DgL-SL8-MCMV.
In summary, our data indicate that IL-33 is necessary for the
optimal development of virus-specific TEM and CD69
+ TRM cells
under conditions of persistent antigenic stimulation and identify a
straightforward approach that can potentiate the therapeutic ben-
efits of recombinant immunogens vectored by replication-deficient
strains of CMV. Although further studies are required to validate
these findings in other systems, we anticipate that the adjuvant
effects of rIL-33 may enhance the general utility of vaccines that
deliver a transient immunogenic stimulus, exemplified in this
study by DgL-SL8-MCMV.
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